Discuss Nektar Therapeutics
Nektar Therapeutics
WKN: 165417 / Symbol: NKTR / Name: Nektar / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
0,58 €
2,03 %
Nektar Therapeutics (NASDAQ:NKTR) had its price target raised by analysts at B. Riley from $85.00 to $105.00. They now have a "buy" rating on the stock.
Ratings data for NKTR provided by MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating.
Ratings data for NKTR provided by MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $102.00 price target on the stock.
Ratings data for NKTR provided by MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) had its price target raised by analysts at HC Wainwright from $120.00 to $135.00. They now have a "buy" rating on the stock.
Ratings data for NKTR provided by MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) had its price target raised by analysts at BTIG Research from $100.00 to $118.00. They now have a "buy" rating on the stock.
Ratings data for NKTR provided by MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Ratings data for NKTR provided by MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $118.00 price target on the stock.
Ratings data for NKTR provided by MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) was upgraded by analysts at William Blair from a "market perform" rating to an "outperform" rating.
Ratings data for NKTR provided by MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) had its price target raised by analysts at BTIG Research from $118.00 to $151.00. They now have a "buy" rating on the stock.
Ratings data for NKTR provided by MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) had its price target raised by analysts at HC Wainwright from $135.00 to $165.00. They now have a "buy" rating on the stock.
Ratings data for NKTR provided by MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) had its "buy" rating reaffirmed by analysts at B. Riley Financial, Inc.. They now have a $150.00 price target on the stock, up previously from $105.00.
Ratings data for NKTR provided by MarketBeat
Nektar Therapeutics (NKTR) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc..
Ratings data for NKTR provided by MarketBeat
Nektar Therapeutics (NKTR) had its price target raised by Citigroup Inc. from $102.00 to $123.00. They now have a "buy" rating on the stock.
Ratings data for NKTR provided by MarketBeat
Nektar Therapeutics (NKTR) is now covered by TD Cowen. They set a "buy" rating on the stock.
Ratings data for NKTR provided by MarketBeat
Neueste Beiträge
Citigroup_Inc_ in Amazon.com Inc. diskutieren